Back to News
Market Impact: 0.3
Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up
Source: Nasdaq
Healthcare & Biotech
Antengene Corporation dosed the first patient in China in the pivotal Phase III CLINCH-3 trial of ATG-022, a CLDN18.2-targeting antibody-drug conjugate. The study advances the commercial-stage biotech's late-stage development program for patients with CLDN18.2-positive disease, although the article excerpt does not provide efficacy, safety, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Why is Labcorp stock sliding today?
- Why is Quest Diagnostics stock sliding today?
- Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs